Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex announced positive preclinical data for their Reqorsa® Gene Therapy in treating Ras inhibitor resistant lung cancer at the 2025 AACR Annual Meeting in Chicago. The research focused on treating KRASG12C mutant non-small cell lung cancer (NSCLC).
Key findings showed that Reqorsa effectively overcomes resistance to LUMAKRAS® (sotorasib) in NSCLC mouse models. The therapy demonstrated significant results both alone and in combination with sotorasib:
- Reduced colony formation and increased cancer cell death in resistant cell lines
- Decreased viability of resistant organoids
- Showed strong anti-tumor effects in controlling tumor growth
- Achieved synergistic anti-tumor effects when combined with sotorasib
The research suggests Reqorsa's potential as a treatment for Ras inhibitor resistant lung cancer, either as a standalone therapy or in combination with Ras inhibitors.
Genprex announced that its research collaborators will present positive preclinical data for their diabetes gene therapy drug candidate GPX-002 at the ASGCT 28th Annual Meeting in New Orleans this May.
The research focuses on a novel gene therapy using recombinant adeno-associated virus (rAAV) to treat diabetes mellitus. Key findings show that retrograde intraductal infusion of rAAV6 successfully delivered Pdx1 and MafA genes, converting alpha cells into insulin-secreting beta-like cells.
Testing on non-human primates demonstrated:
- Improved glucose tolerance and reduced insulin needs one month post-infusion
- Durable effects using AAV6 capsid with endocrine-specific promoters
- Successful immune response management using temporary immunosuppression
- Sustained therapeutic effects even after stopping immunosuppression
The research represents a potential breakthrough in diabetes treatment, with results showing sustained therapeutic effects without long-term immunosuppression requirements.
Genprex (NASDAQ: GNPX) has signed an exclusive patent license agreement with NYU Langone Health for Reqorsa® Gene Therapy to treat mesothelioma. The therapy shows promising preclinical results in treating Malignant Pleural Mesothelioma (MPM).
Research data presented at the 2024 EORTC-NCI-AACR Symposium demonstrated that REQORSA significantly decreased cell proliferation and invasion while increasing cell apoptosis in MPM cell lines. The therapy utilizes the TUSC2 tumor suppressor gene, which is downregulated in 84% of mesotheliomas.
Genprex formed a Mesothelioma Clinical Advisory Board in 2024 with four leading researchers to support its preclinical program. According to CDC data, mesothelioma affects approximately 3,000 new cases annually in the U.S., with a life expectancy of 18 months and a 3-year survival rate of 23% with treatment.
Genprex (NASDAQ: GNPX) has been selected to present at the 2025 ASCO Annual Meeting in Chicago, showcasing their Acclaim-3 Phase 1/2 clinical trial design. The presentation will focus on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC).
The presentation is scheduled for May 31, 2025, from 1:30 to 4:30 p.m. CT, and will be delivered by Dr. Bo Wang from Oncology Associates of Oregon. The abstract will be featured in the Trials in Progress poster session, highlighting the company's innovative approach in cancer treatment development.
Genprex (NASDAQ: GNPX) announced the publication of their research collaborators' abstract in Cancer Research's online Proceedings supplement. The abstract, which will be presented at the 2025 AACR Annual Meeting, showcases positive preclinical data for Reqorsa® Gene Therapy in treating KRASG12C mutant non-small cell lung cancer (NSCLC).
The research demonstrates that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy, particularly when combined with sotorasib in resistant tumors.
Genprex announced that its research collaborators will present positive preclinical data for Reqorsa® Gene Therapy at the 2025 AACR Annual Meeting in Chicago. The study focuses on treating KRASG12C mutant non-small cell lung cancer (NSCLC), particularly addressing resistance to Lumakras® (sotorasib).
The preclinical data demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy both as a standalone therapy and in combination with sotorasib in resistant tumors.